{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:40:08Z","timestamp":1787002808075,"version":"build-2736575974"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,10,23]],"date-time":"2017-10-23T00:00:00Z","timestamp":1508716800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1038\/onc.2017.348","type":"journal-article","created":{"date-parts":[[2017,10,23]],"date-time":"2017-10-23T16:04:18Z","timestamp":1508774658000},"page":"722-731","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP)"],"prefix":"10.1038","volume":"37","author":[{"given":"T","family":"Mitamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Pradeep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S Y","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Hatakeyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y A","family":"Lyons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Hisamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Noh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Villar-Prados","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Ivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Rodriguez-Aguayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Lopez-Berestein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R L","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A K","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,23]]},"reference":[{"key":"BFonc2017348_CR1","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s10555-007-9094-7","volume":"26","author":"F Hillen","year":"2007","unstructured":"Hillen F, Griffioen AW . Tumour vascularization: sprouting angiogenesis and beyond. Cancer Metastasis Rev 2007; 26: 489\u2013502.","journal-title":"Cancer Metastasis Rev"},{"key":"BFonc2017348_CR2","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/362841a0","volume":"362","author":"KJ Kim","year":"1993","unstructured":"Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor-growth invivo. Nature 1993; 362: 841\u2013844.","journal-title":"Nature"},{"key":"BFonc2017348_CR3","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","volume":"365","author":"RA Burger","year":"2011","unstructured":"Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011; 365: 2473\u20132483.","journal-title":"N Engl J Med"},{"key":"BFonc2017348_CR4","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","volume":"365","author":"TJ Perren","year":"2011","unstructured":"Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011; 365: 2484\u20132496.","journal-title":"N Engl J Med"},{"key":"BFonc2017348_CR5","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","volume":"32","author":"E Pujade-Lauraine","year":"2014","unstructured":"Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol 2014; 32: 1302\u20131308.","journal-title":"J Clin Oncol"},{"key":"BFonc2017348_CR6","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335\u20132342.","journal-title":"N Engl J Med"},{"key":"BFonc2017348_CR7","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa061884","volume":"355","author":"A Sandler","year":"2006","unstructured":"Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542\u20132550.","journal-title":"N Engl J Med"},{"key":"BFonc2017348_CR8","doi-asserted-by":"publisher","first-page":"5422","DOI":"10.1200\/JCO.2008.16.9847","volume":"26","author":"BI Rini","year":"2008","unstructured":"Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008; 26: 5422\u20135428.","journal-title":"J Clin Oncol"},{"key":"BFonc2017348_CR9","doi-asserted-by":"publisher","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","volume":"27","author":"HS Friedman","year":"2009","unstructured":"Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 27: 4733\u20134740.","journal-title":"J Clin Oncol"},{"key":"BFonc2017348_CR10","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1038\/nbt1210-1248","volume":"28","author":"M Uhlen","year":"2010","unstructured":"Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M et al. Towards a knowledge-based Human Protein Atlas. Nat Biotechnol 2010; 28: 1248\u20131250.","journal-title":"Nat Biotechnol"},{"key":"BFonc2017348_CR11","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.4049\/jimmunol.1300758","volume":"192","author":"X Pei","year":"2014","unstructured":"Pei X, Sun Q, Zhang Y, Wang P, Peng X, Guo C et al. PC3-secreted microprotein is a novel chemoattractant protein and functions as a high-affinity ligand for CC chemokine receptor 2. J Immunol 2014; 192: 1878\u20131886.","journal-title":"J Immunol"},{"key":"BFonc2017348_CR12","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1515\/BC.2007.032","volume":"388","author":"C Valtonen-Andre","year":"2007","unstructured":"Valtonen-Andre C, Bjartell A, Hellsten R, Lilja H, Harkonen P, Lundwall A . A highly conserved protein secreted by the prostate cancer cell line PC-3 is expressed in benign and malignant prostate tissue. Biol Chem 2007; 388: 289\u2013295.","journal-title":"Biol Chem"},{"key":"BFonc2017348_CR13","doi-asserted-by":"publisher","first-page":"D670","DOI":"10.1093\/nar\/gku1177","volume":"43","author":"KR Rosenbloom","year":"2015","unstructured":"Rosenbloom KR, Armstrong J, Barber GP, Casper J, Clawson H, Diekhans M et al. The UCSC Genome Browser database: 2015 update. Nucleic Acids Res 2015; 43: D670\u2013D681.","journal-title":"Nucleic Acids Res"},{"key":"BFonc2017348_CR14","doi-asserted-by":"publisher","first-page":"D56","DOI":"10.1093\/nar\/gks1172","volume":"41","author":"KR Rosenbloom","year":"2013","unstructured":"Rosenbloom KR, Sloan CA, Malladi VS, Dreszer TR, Learned K, Kirkup VM et al. ENCODE data in the UCSC Genome Browser: year 5 update. Nucleic Acids Res 2013; 41: D56\u2013D63.","journal-title":"Nucleic Acids Res"},{"key":"BFonc2017348_CR15","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1101\/gad.277863.116","volume":"30","author":"R Ghirlando","year":"2016","unstructured":"Ghirlando R, Felsenfeld G . CTCF: making the right connections. Genes Dev 2016; 30: 881\u2013891.","journal-title":"Genes Dev"},{"key":"BFonc2017348_CR16","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/86507","volume":"7","author":"MS Kim","year":"2001","unstructured":"Kim MS, Kwon HJ, Lee YM, Baek JH, Jang JE, Lee SW et al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 2001; 7: 437\u2013443.","journal-title":"Nat Med"},{"key":"BFonc2017348_CR17","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s11060-011-0717-z","volume":"107","author":"J Drappatz","year":"2012","unstructured":"Drappatz J, Lee EQ, Hammond S, Grimm SA, Norden AD, Beroukhim R et al. Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma. J Neurooncol 2012; 107: 133\u2013138.","journal-title":"J Neurooncol"},{"key":"BFonc2017348_CR18","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1093\/neuonc\/nou350","volume":"17","author":"EQ Lee","year":"2015","unstructured":"Lee EQ, Reardon DA, Schiff D, Drappatz J, Muzikansky A, Grimm SA et al. Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma. Neuro Oncol 2015; 17: 862\u2013867.","journal-title":"Neuro Oncol"},{"key":"BFonc2017348_CR19","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00280-012-1911-1","volume":"70","author":"JH Strickler","year":"2012","unstructured":"Strickler JH, Starodub AN, Jia J, Meadows KL, Nixon AB, Dellinger A et al. Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors. Cancer Chemother Pharmacol 2012; 70: 251\u2013258.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BFonc2017348_CR20","doi-asserted-by":"publisher","first-page":"11941","DOI":"10.1093\/nar\/gku937","volume":"42","author":"O Weth","year":"2014","unstructured":"Weth O, Paprotka C, Gunther K, Schulte A, Baierl M, Leers J et al. CTCF induces histone variant incorporation, erases the H3K27me3 histone mark and opens chromatin. Nucleic Acids Res 2014; 42: 11941\u201311951.","journal-title":"Nucleic Acids Res"},{"key":"BFonc2017348_CR21","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1172\/JCI110380","volume":"68","author":"RC Bast Jr.","year":"1981","unstructured":"Bast RC Jr., Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC . Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981; 68: 1331\u20131337.","journal-title":"J Clin Invest"},{"key":"BFonc2017348_CR22","first-page":"3668","volume":"45","author":"RN Buick","year":"1985","unstructured":"Buick RN, Pullano R, Trent JM . Comparative properties of five human ovarian adenocarcinoma cell lines. Cancer Res 1985; 45: 3668\u20133676.","journal-title":"Cancer Res"},{"key":"BFonc2017348_CR23","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1593\/neo.08740","volume":"10","author":"CN Landen","year":"2008","unstructured":"Landen CN, Kim TJ, Lin YG, Merritt W, Kamat AA, Han L et al. Tumor-selective response to antibody-mediated targeting of alpha(v)beta(3) integrin in ovarian cancer. Neoplasia 2008; 10: 1259\u20131267.","journal-title":"Neoplasia"},{"key":"BFonc2017348_CR24","first-page":"5181","volume":"51","author":"DH Lau","year":"1991","unstructured":"Lau DH, Lewis AD, Ehsan MN, Sikic BI . Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin. Cancer Res 1991; 51: 5181\u20135187.","journal-title":"Cancer Res"},{"key":"BFonc2017348_CR25","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1093\/jnci\/90.6.447","volume":"90","author":"J Yoneda","year":"1998","unstructured":"Yoneda J, Kuniyasu H, Crispens MA, Price JE, Bucana CD, Fidler IJ . Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J Natl Cancer Inst 1998; 90: 447\u2013454.","journal-title":"J Natl Cancer Inst"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/onc2017348.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/onc2017348","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/onc.2017.348","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/onc2017348.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T01:02:14Z","timestamp":1684458134000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/onc2017348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,23]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["BFonc2017348"],"URL":"https:\/\/doi.org\/10.1038\/onc.2017.348","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,23]]},"assertion":[{"value":"6 November 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}